Heart Disease News and Research

Latest Heart Disease News and Research

PROSPECT clinical trial results announced

Abbott today announced primary results from its groundbreaking PROSPECT (Providing Regional Observations to Study Predictors of Events in the Coronary Tree) clinical trial.

25 Sep 2009

Dems court Snowe for key 60th vote

Democrats are courting Sen. Olympia Snowe, R-Me., the Republican most likely to provide the key 60th vote that Democrats need to pass a health care overhaul package without the use of budget reconciliation.

25 Sep 2009

Investment in preventative healthcare is vital during recession: Experts

In these economically challenging times, many experts say it is vital to invest in preventative healthcare. Better overall health means lower medical bills.

25 Sep 2009

Webcast on the treatment of cardiovascular diseases

On September 24th at 7:00pm EDT, Dr. Holly Andersen, Director of Education and Outreach at the Ronald O. Perelman Heart Institute at NewYork-Presbyterian Hospital/Weill Cornell Medical Center, will host a live webcast exploring the advances and innovations in the treatment of cardiovascular disease. The air live on ORLive.com from the Hospital's new Ronald O. Perelman Heart Institute.

25 Sep 2009

Tooth cell banking for the treatment of future diseases

Pioneered by BioEDEN, tooth cell banking is a safe, natural and wholly non-invasive method of collecting and preserving precious stem cells which could hold the key to children's health.

25 Sep 2009

Diabetes prevalence highest in the Southern and Appalachian states

Diabetes prevalence is highest in the Southern and Appalachian states and lowest in the Midwest and the Northeast of America. Researchers writing in BioMed Central's open access journal Population Health Metrics have used two public data sources to investigate the prevalence of diagnosed and undiagnosed diabetes mellitus at the State level.

25 Sep 2009

Pakistan cardiology institute purchases Positron's Pulse compact digital cardiac camera

Positron Corporation a molecular imaging solutions company focused on Nuclear Cardiology, announces the sale of a Pulse CDCC camera to CPE Institute Of Cardiology in Multan, Pakistan.

25 Sep 2009

Social disparities in the treatment of cardiovascular diseases

Since the introduction of statins to treat high cholesterol, the decline in lipid levels experienced by the wealthy has been double that experienced by the poor. While statins are highly effective in reducing cholesterol and improving heart health, their use may have contributed to expanding social disparities in the treatment of cardiovascular disease, according to research by Virginia W. Chang, MD, PhD, of the Philadelphia Veterans Affairs Medical Center and the University of Pennsylvania, and Diane S. Lauderdale, PhD, of the University of Chicago, published in the September issue of Journal of Health and Social Behavior.

25 Sep 2009

Matrix metalloproteinase-8 enzyme increases the risk of heart diseases

Scientists at Queen Mary, University of London have made an important discovery in understanding what causes arteries to clog up. They have discovered that an enzyme called matrix metalloproteinase-8 plays a crucial role in raising blood pressure and causing abnormal build-up of cells in the arteries - both of which increase the risk of heart disease.

25 Sep 2009

Combination drug to limit the dangerous side effects of morphine

University of Michigan scientists have developed a combination drug that promises a safer, more precise way for medics and fellow soldiers in battle situations to give a fallen soldier both morphine and a drug that limits morphine's dangerous side effects.

25 Sep 2009

Multi-modality imaging to identify plaque

Late-breaking results from the PROSPECT clinical trial shed new light on the types of vulnerable plaque that are most likely to cause sudden, unexpected adverse cardiac events, and on the ability to identify them through imaging techniques before they occur.

25 Sep 2009

Interim results of a pilot study using BACE cardiac device released

Mardil, Inc. today announced positive interim data from a pilot study investigating the safety and efficacy of its novel cardiac device - BACE (Basal Annuloplasty of the Cardia Externally) -- in treating mitral valve regurgitation. The condition arises when the heart's mitral valve leaks blood backward into the heart, causing a range of severe and debilitating symptoms.

25 Sep 2009

Athera Biotechnologies and ALPCO sign distribution agreement

Athera Biotechnologies AB, an atherosclerosis R&D company developing novel products for treatment and prevention of cardiovascular disease (CVD), and ALPCO, a company providing high quality research immunoassays, announced today that they have signed a distribution agreement.

25 Sep 2009

Oxygen Biotherapeutics submits a patent application for its heart attack treatment device

Oxygen Biotherapeutics, Inc. today announced that the company has submitted a patent application for a new invention that uses Oxycyte(R) perfluorocarbon to deliver oxygen as a first aid treatment for victims of heart attacks and strokes. Oxycyte is the Company's perfluorocarbon (PFC) therapeutic oxygen carrier.

24 Sep 2009

Karo Bio announces clinical phase II results of thyroid hormone analog eprotirome

The Swedish biotech company Karo Bio today announced that results from a clinical phase II study of the company’s thyroid hormone analog eprotirome, and its additive effects on dyslipidemia in ezetimibe-treated patients, are subject to a scientific presentation.

24 Sep 2009

William A. Berry & Son acquired by Suffolk Construction Company

Suffolk Construction Company, New England’s largest construction company announced today that they have acquired William A. Berry & Son (Berry), the second largest construction company in the region.

24 Sep 2009

Stereotaxis showcases its remote magnetic navigation technology at TCT symposium

Stereotaxis, Inc. is showcasing the value of its technologies for interventional procedures at the Transcatheter Cardiovascular Therapeutics (TCT) symposium in San Francisco this week.

24 Sep 2009

Everolimus-eluting stent efficient in treating native coronary artery lesions

Late-breaking data from SPIRIT IV, a large-scale multi-center study of nearly 4,000 patients in the U.S., shows that an everolimus-eluting stent demonstrated enhanced safety and efficacy in the treatment of de novo native coronary artery lesions when compared to a paclitaxel-eluting stent, and showed that "low late loss" may be achieved with drug-eluting stents without sacrificing safety.

24 Sep 2009

District court of Frankfurt, Germany rules in favour of Occlutech

Occlutech GmbH, the leading European developer of products for septal closure, today announced that the district court of Frankfurt, Germany reversed an earlier court injunction obtained by AGA Medical against Occlutech's sales and marketing activities relating to the newly launched Figulla Flex ranges of ASD and PFO occluders.

24 Sep 2009

Clinical trial comparing Boston Scientific's coronary stent systems

Boston Scientific Corporation today welcomed one-year data from the SPIRIT IV clinical trial comparing the XIENCE V((R)) (PROMUS((R))) Everolimus-Eluting Coronary Stent System to the TAXUS((R)) Express2(TM) Paclitaxel-Eluting Coronary Stent System. The results support the benefits of paclitaxel-eluting stents in diabetic patients. The trial enrolled 3,690 patients, including 1,140 diabetics, the largest diabetic subset ever studied in a drug-eluting stent clinical trial.

24 Sep 2009